Dihydroquercetin (Taxifolin): pharmacological effect and possible use in patients with COVID-19

DOI: https://doi.org/10.29296/25419218-2023-02-01
Issue: 
2
Year: 
2023

1-Tver State Medical University, Sovetskaya str., 4, Tver, Tver region, 170100, Russian Federation;
2-Regional Clinical Cardiology Centre, Komsomolsky Prospect, 19, Tver Region, Tver, 170041, Russian Federation

Introduction. Dihydroquercetin (Taxifolin) was produced on an industrial scale as a pharmaceutical substance from Siberian or Dahurian larch. Study objective. To study literature data reflecting the results of investigation of antioxidant, antiviral, anti-inflammatory, immunomodulating effects of dihydroquercetin (taxifolin), to evaluate the possibility of application of this drug in complex treatment and prevention of COVID-19 complications. Material and methods. Scientific review and analysis of 26 publications of scientists from the Russian Federation, China, European Union, Iran, India, United States, Italy, United Kingdom, Switzerland, France, Ukraine, Norway, Saudi Arabia, Greece, which reflected the results of study of antioxidant, antiviral, anti-inflammatory, immunomodulatory effects of dihydroquercetin (taxifolin), including in COVID-19 patients, were performed in the work. Results. In the publications, the authors acknowledged that dihydroquercetin (taxifolin) had high antioxidant activity. They presented evidence for the use of quercetin to treat patients with COVID-19 as an additional promising pharmacological agent and identified its immunomodulatory effects. An article by scientists from Italy provided evidence that the substance could inhibit the replication of SARS-CoV-2. A publication by scientists in Saudi Arabia and India found the therapeutic and preventive effects of quercetin in patients with COVID-19. In addition, the use of this drug in patients with postcovid syndrome has been discussed in the literature. Some of the publications noted the possibility of using this drug in the treatment of inflammation, infections and oxidative stress. Researchers have identified antiviral and anti-inflammatory effects of the drug, including in men and women with COVID-19. Conclusion. Dihydroquercetin (Taxifolin) had antiviral, antioxidant, immunomodulatory, anti-inflammatory effects and apparently could be promising for possible use in the complex treatment and prevention, including in patients with COVID-19.
Keywords: 
flavanoids
quercetin
dihydroquverticin
taxifolin
antiviral
action
patients
treatment
prevention
COVID-19
References: 
  1. Ivanov I.S., Sidekhmenova A.V., Tyukavkina N.A. et al. Effect of dihydroquercetin on the tone of isolated rat veins. Bulletin of Experimental Biology and Medicine. 2013; 155 (1): 65–6.
  2. Зеня Е.Н., Савватеев А.М., Тюкавкина Н.А и др. Определение компонентов композиции биофлавоноидного комплекса "Дигидрокверцетин" и экстракта семян льна. Фармация. 2012; 1: 16-9. [Zenya E.N., Savvateev A.M. , Tyukavkina N.A i dr. Determination of the components of the composition of the bioflavonoid complex Dihydroquercetin and flax seed extract. Farmaciya. 2012; 1: 16–9] (in Russian)].
  3. Зеня Е.Н., Ильясов И.Р., Тюкавкина Н.А и др. Оценка антирадикальных свойств экстракта семян льна и его композиций с дигидрокверцетином. Бутлеровские сообщения. 2012; 29 (1): 62–7. [Zenya E.N., Il`yasov I.R., Tyukavkina N.A i dr. Evaluation of antiradical properties of flax seed extract and its compositions with dihydroquercetin. Butlerovskie soobshheniya. 2012; 29 (1): 62–7] (in Russian)].
  4. Plotnikov M.B., Aliev O.I., Maslov M.J. et al. Correction of haemorheological disturbances in myocardial infarction by diquertin and ascorbic acid. Phytotherapy Research. 2003; 17 (1): 86–8.
  5. Teselkin Yu.O., Babenkova I.V., Kolhir V.K. et al. Dihydroquercetin as a means of antioxidative defence in rats with tetrachloromethane hepatitis. Phytotherapy Research. 2000; 14 (3): 160–2.
  6. Kubatiev A.A., Yadigarova Z.T., Rud'ko I.A. et al. Diquertin suppresses adp- and thrombin-induced accumulation of cytoplasmic calcium in human thrombocytes. Pharmaceutical Chemistry J. 1999; 33 (12): 629–30.
  7. Терехов Р.П. Влияние фазового состояния на физико-химические, технологические и биофармацевтические параметры дигидрокверцетина. Диссертация на соискание ученой степени кандидата фармацевтических наук. 2021; 173. [Terexov R.P. Influence of phase state on physico-chemical, technological and biopharmaceutical parameters of dihydroquercetin. Dissertation for the degree of Candidate of Pharmaceutical Sciences. 2021; 173 (in Russian)].
  8. Ковалевская Е.Г. Оптимизация условий производства субстанции дигидрокверцетина, разработка лекарственного препарата на ее основе. Автореферат диссертации на соискание ученой степени кандидата фармацевтических наук. 2014; 24. [Kovalevskaya E.G. Optimization of production conditions of Dihydroquercetin substance, development of a drug based on it. Author's abstract of the thesis for the degree of Candidate of Pharmaceutical Sciences. 2014; 24 (in Russian)].
  9. Sunil C., Xu B. An insight into the health-promoting effects of taxifolin (dihydroquercetin). Phytochemistry. 2019; 166: 112066. DOI: 10.1016/j.phytochem.2019.112066
  10. Zhu Y., Scholle F., Kisthardt S.C. et al. Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E. Virology. 2022; 571: 21–33. DOI: 10.1016/j.virol.2022.04.005
  11. Wang W., Ma B.L., Xu C.G. et al. Dihydroquercetin protects against renal fibrosis by activating the Nrf2 pathway. Phytomedicine. 2020; 69: 153185. DOI: 10.1016/j.phymed.2020.153185
  12. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D., Bresson J.-L., Burlingame B. et al. 2017. Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA J. 2017; 15 (2): 4682, 16. DOI: 10.2903/j.efsa.2017.4682
  13. Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Министерство здравоохранения Российской Федерации. 2022; 249. [Provisional Methodological Recommendations for Prevention, Diagnosis and Treatment of New Coronavirus Infection (COVID-19). Ministry of Health of the Russian Federation. 2022; 249 (in Russian)].
  14. Seyed Hosseini E., Riahi Kashani N., Nikzad H. et al. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020; 551: 1–9. DOI: 10.1016/j.virol.2020.08.011
  15. Xie M., Chen Q. Insight into 2019 novel coronavirus – An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J. Infect Dis. 2020; 94: 119–24. DOI: 10.1016/j.ijid.2020.03.071
  16. Boehm E., Kronig I., Neher R.A. et al. Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021; 27 (8): 1109–17. DOI: 10.1016/j.cmi.2021.05.022
  17. Manjunath S.H., Thimmulappa R.K. Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. J. Pharm Anal. 2022; 12 (1): 29–34. DOI: 10.1016/j.jpha.2021.09.009
  18. Colunga Biancatelli R.M.L., Berrill M., Catravas J.D. et al. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol. 2020; 11: 1451. DOI: 10.3389/fimmu.2020.01451
  19. Gasmi A., Mujawdiya P.K., Lysiuk R. et al. Quercetin in the Prevention and Treatment of Coronavirus Infections: A Focus on SARS-CoV-2. Pharmaceuticals (Basel). 2022; 15 (9): 1049. DOI: 10.3390/ph15091049
  20. Derosa G., Maffioli P., D'Angelo A. et al. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 2021; 35 (3): 1230–6. doi: 10.1002/ptr.6887
  21. Imran M., Thabet H.K., Alaqel S.I. et al. The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature. Antioxidants (Basel). 2022; 11 (5): 876. DOI: 10.3390/antiox11050876
  22. Catalano A., Iacopetta D., Ceramella J. et al. Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment? Foods. 2022; 11 (18): 2884. DOI: 10.3390/foods11182884
  23. Saeedi-Boroujeni A., Mahmoudian-Sani M.R. Anti-inflammatory potential of Quercetin in COVID-19 treatment. J. Inflamm (Lond). 2021; 18 (1): 3. DOI: 10.1186/s12950-021-00268-6
  24. Alam Q., Krishnamurthy S. Dihydroquercetin ameliorates LPS-induced neuroinflammation and memory deficit. Curr Res Pharmacol Drug Discov. 2022; 3: 100091. DOI: 10.1016/j.crphar.2022.10009
  25. Orlova S.V., Tatarinov V.V., Nikitina E.A. et al. Bioavailability and Safety of Dihydroquercetin (Review). Pharm Chem J. 2022; 55 (11): 1133–7. DOI: 10.1007/s11094-022-02548-8
  26. Дедов Д.В. Дигидрокверцетин: фармакологические свойства, возможность применения препарата в клинической практике. Врач. 2022; 33 (10): 78–80. [Dedov D.V. Dihydroquercetin: pharmacological properties, possibility of using the drug in clinical practice. Vrach. 2022; 33 (10): 78–80. DOI 10.29296/25877305-2022-10-16 – EDN UZLQQR (in Russian)].